Collectively, our findings provide biological insight in the biology underlying predisposition to BCR following EBRT ± ADT and open additional avenues for investigation to target TGF-β signaling in the high risk localized prostate cancer setting. This evidence concerns the gene BCR and Familial prostate cancer.